Check-Cap (NASDAQ:CHEK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

CHEK has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective (up from $6.00) on shares of Check-Cap in a report on Thursday, September 28th. Maxim Group restated a “buy” rating and set a $5.00 price target on shares of Check-Cap in a research note on Wednesday, September 27th. Finally, ValuEngine upgraded Check-Cap from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $4.63.

Check-Cap (CHEK) traded down $0.07 during mid-day trading on Friday, hitting $0.91. The stock had a trading volume of 502,063 shares, compared to its average volume of 61,075. Check-Cap has a 1-year low of $0.88 and a 1-year high of $2.70.

A hedge fund recently raised its stake in Check-Cap stock. Sabby Management LLC lifted its stake in shares of Check-Cap Ltd. (NASDAQ:CHEK) by 467.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,418,893 shares of the medical research company’s stock after purchasing an additional 1,169,061 shares during the quarter. Check-Cap comprises approximately 0.1% of Sabby Management LLC’s portfolio, making the stock its 24th biggest position. Sabby Management LLC owned about 8.36% of Check-Cap worth $2,724,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/01/check-cap-chek-downgraded-by-zacks-investment-research.html.

About Check-Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Get a free copy of the Zacks research report on Check-Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.